Myeloid Leukemia News and Research

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Prolonged exposure to formaldehyde linked with increased risk of myeloid leukemia

21. November 2009 00:45

Long durations of exposure to formaldehyde used for embalming in the funeral industry were associated with an increased risk of death from myeloid leukemia, according to a new study published online November 20 in the Journal of the National Cancer Institute. [More]

35e495fd-98b7-493d-b8a4-f4170faa0512|0|.0

Posted in: Medical Condition News

Tags: Brain, Brain Cancer, Cancer, Formaldehyde, Genetics, Leukaemia, Leukemia, Myeloid Leukemia

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

18. November 2009 08:40

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models. [More]

7105e9d6-13ab-4fd4-afa9-3e55eccba03a|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Acute Lymphoblastic Leukemia, Apoptosis, Breast Cancer, Cancer, Cell, Chronic Myeloid Leukemia, Colon Cancer, Erlotinib, Gleevec, Hospital, Leukemia, Lung Cancer, Lymphoma, Melanoma, Multiple Myeloma, Myeloid Leukemia, Non-Small Cell Lung Cancer, Oncology, Paclitaxel, Pancreatic Cancer, Prostate Cancer, Small Cell Lung Cancer, Sunitinib, Tarceva, Xenograft

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

17. November 2009 05:02

To highlight results of more recent research, the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference will host a press briefing on "Drugs in the Pipeline." Sara A. Courtneidge, Ph.D., D.Sc., professor and director of the Tumor Microenvironment Program, and director of academic affairs at the Burnham Institute for Medical Research, will moderate this press briefing. [More]

ac48c877-eb35-45fc-9d99-0eb9b9d6de31|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Acetylation, Adenosine, Amino Acid, Anemia, Angiogenesis, Autophagy, Blood Pressure, Breast Cancer, Cancer, Cediranib, Cell, Chemotherapy, Colorectal Cancer, Diarrhea, DNA, Gene Expression, Hematology, Leukemia, Myeloid Leukemia, Nausea, Oncology, Ovarian Cancer, Radiotherapy, Stem Cell, Stress, Vomiting

Two units of UCB reduce risk of leukemia from returning, shows new study

16. November 2009 01:27

A new study from the Masonic Cancer Center, University of Minnesota shows that patients who have acute leukemia and are transplanted with two units of umbilical cord blood (UCB) have significantly reduced risk of the disease returning. [More]

2c828feb-37c0-4d34-b204-b3fb546c2d10|0|.0

Posted in: Medical Science News | Medical Condition News

Tags: Acute Lymphoblastic Leukemia, Bone, Bone Marrow, Cancer, Cell, Education, Hematology, Hospital, Leukemia, Myeloid Leukemia, Oncology, Pediatrics, Placenta, Stem Cell, Transplant

Sprycel holds hope for treating Src dependent ovarian cancer

11. November 2009 01:00

The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. [More]

034f3dca-cb4c-46c0-a8c9-7be652652d7a|0|.0

Posted in: Women's Health News | Pharmaceutical News

Tags: Breast Cancer, Cancer, Cell, Chemotherapy, Chronic Myeloid Leukemia, Education, Gene Expression, Hematology, Kinase Inhibitor, Leukemia, Myeloid Leukemia, Oncology, Ovarian Cancer, Sprycel

EpiCept announces third quarter 2009 financial results

10. November 2009 00:45

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates. [More]

84e877a4-3312-4b4a-8cb7-dbd6b5658da1|0|.0

Posted in: Business / Finance

Tags: Apoptosis, Bone, Bone Marrow, Bone Marrow Disease, Cancer, Cell, Evolution, Exercise, Gabapentin, Genetics, Histamine, Interleukin-2, Leukemia, Myeloid Leukemia, Neuralgia, New Drug Application, Oncology, Pharmacology

FDA accepts ChemGenex Pharmaceuticals' NDA for Omapro

10. November 2009 00:08

ChemGenex Pharmaceuticals Limited announced today that the U.S. Food & Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for Omapro™ (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation. [More]

6424e3a8-683b-423e-8d46-90c9dff25119|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Bone, Bone Marrow, Cancer, Cell, Chronic Myeloid Leukemia, Hematology, Leukemia, Myeloid Leukemia, New Drug Application, Omacetaxine, Oncology

CytRx reports financial results for the three months and nine months ended September 30, 2009

9. November 2009 09:17

CytRx Corporation, a biopharmaceutical company, today reported financial results for the three months and nine months ended September 30, 2009. [More]

501b5920-8b6e-4819-adb5-ce67f9a54d60|0|.0

Posted in: Business / Finance

Tags: Arsenic, Brain, Breast Cancer, Cancer, Cell, Chromosome, Chronic Myeloid Leukemia, Doxorubicin, Gleevec, Investment, Kinase Inhibitor, Leukemia, Myeloid Leukemia, Oncology, Ovarian Cancer, Pancreatic Cancer, Retinoic Acid, Stroke

Health Canada accepts for review the EpiCept’s New Drug Submission for Ceplene

9. November 2009 01:28

EpiCept Corporation today announced that Health Canada has accepted for review the Company’s New Drug Submission (NDS) for Ceplene® (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first complete remission. [More]

45de2b1f-a86a-4dda-bcd3-a05de93e1367|1|5.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Apoptosis, Cancer, Genetics, Hematology, Histamine, Leukemia, Myeloid Leukemia, Oncology

FDA grants orphan drug designation for Sunesis Pharmaceuticals' voreloxin

6. November 2009 01:56

Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML. [More]

304215af-4ddf-4196-b671-35f1a9c2b302|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Apoptosis, Bone, Bone Marrow, Cancer, Chemotherapy, DNA, Leukemia, Lymphoma, Myeloid Leukemia, Oncology, Ovarian Cancer, Rare Disease, Voreloxin

Successful leukemia treatment with a radiolabeled antibody followed by stem cell transplant

6. November 2009 01:46

For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options. [More]

5a356df4-15a4-4096-a3ea-b2a3a8d24579|0|.0

Posted in: Medical Science News | Medical Condition News

Tags: Antibody, Cancer, Cell, Chemotherapy, HIV/AIDS, Leukemia, Lymphoma, Myeloid Leukemia, Nuclear Medicine, Pediatrics, Stem Cell, Transplant

Scientists discover two genes that can lead to aggressive leukaemia

3. November 2009 23:32

Two genes, each one of which is known to cause cancer on its own, together can lead to aggressive leukaemia. This is the conclusion from new research carried out on gene-modified mice at the Sahlgrenska Academy at the University of Gothenburg, Sweden. The discovery has surprised scientists, and may lead to new treatments. [More]

15c06f76-8053-41cc-aaa7-ddb47c808c14|0|.0

Posted in: Medical Science News | Medical Condition News

Tags: Blood Cancer, Cancer, Cell, Cell Proliferation, Leukaemia, Leukemia, Myeloid Leukemia

EntreMed to present its Aurora A/angiogenic kinase inhibitor data at the AACR-NCI-EORTC conference

3. November 2009 08:00

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held November 15-19, 2009 in Boston, Massachusetts. Presentations are listed below. [More]

76e948f7-1682-41ef-9592-c27fcfaad8a9|0|.0

Posted in: Drug Trial News | Medical Condition News | Pharmaceutical News

Tags: Arthritis, Breast Cancer, Cancer, Cell, Chemotherapy, Kinase Inhibitor, Leukemia, Multiple Myeloma, Myeloid Leukemia, Pathology, Rheumatoid Arthritis

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

3. November 2009 00:22

ARIAD Pharmaceuticals, Inc. today announced that the scientific journal, Cancer Cell, has published a comprehensive paper describing the design and preclinical characterization of AP24534, ARIAD’s investigational, multi-targeted kinase inhibitor. [More]

13087f56-bf68-4398-815b-530a0b3d446a|0|.0

Posted in: Medical Science News | Medical Condition News

Tags: Cancer, Cell, Chronic Myeloid Leukemia, Dasatinib, Gleevec, Kinase Inhibitor, Leukemia, Myeloid Leukemia, Sprycel

Sunesis Pharmaceuticals enrolls 113 patients in voreloxin REVEAL-1 trial

30. October 2009 08:46

Sunesis Pharmaceuticals, Inc. today reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules. [More]

c7b8b374-b497-446b-a68a-1805941670ef|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Apoptosis, Bone, Bone Marrow, Cancer, Chemotherapy, DNA, Leukemia, Lymphoma, Myeloid Leukemia, Oncology, Ovarian Cancer, Voreloxin

<< Previous posts

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.

Free!

Recent Comments

Twitter

Information

Myeloid Leukemia News and Research

Prolonged exposure to formaldehyde linked with increased risk of myeloid leukemia

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

Two units of UCB reduce risk of leukemia from returning, shows new study

Sprycel holds hope for treating Src dependent ovarian cancer

EpiCept announces third quarter 2009 financial results

FDA accepts ChemGenex Pharmaceuticals' NDA for Omapro

CytRx reports financial results for the three months and nine months ended September 30, 2009

Health Canada accepts for review the EpiCept’s New Drug Submission for Ceplene

FDA grants orphan drug designation for Sunesis Pharmaceuticals' voreloxin

Successful leukemia treatment with a radiolabeled antibody followed by stem cell transplant

Scientists discover two genes that can lead to aggressive leukaemia

EntreMed to present its Aurora A/angiogenic kinase inhibitor data at the AACR-NCI-EORTC conference

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

Sunesis Pharmaceuticals enrolls 113 patients in voreloxin REVEAL-1 trial

Recent Articles

Free!

Recent Comments

Twitter

Information

Myeloid Leukemia News and Research

Medical News Cloud

Recent Articles